Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 346 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetic Retinopathy Clear all
Terminated No phase listed Observational

Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

NCT01717937
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Retinopathy, Hypertensive Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion
Interventions
Phase variance optical coherence tomography (PV-OCT)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 6, 2026, 1:41 PM EDT
Completed Not applicable Interventional Results available

Triamcinolone vs. Laser for Diabetic Macular Edema

NCT00229931
View directory record Official record
Conditions
DIABETIC MACULAR EDEMA
Interventions
Triamcinolone acetonide, laser
Drug · Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 6, 2026, 1:41 PM EDT
Not listed No phase listed Observational

An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity

NCT05566717
View directory record Official record
Conditions
Diabetic Retinopathy, Neurotrophic Keratitis
Interventions
Not listed
Lead sponsor
Medical Center Ophthalmology Associates
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 6, 2026, 1:41 PM EDT
Completed Phase 3 Interventional Results available

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

NCT00542178
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Hypoglycemic Agents, Standard glycemia control, Intensive BP treatment, Standard BP control, Fenofibrate, Simvastatin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
3,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 6, 2026, 1:41 PM EDT
Withdrawn Phase 1 Interventional

The Role of Prostaglandins in the Progression of Diabetic Retinopathy

NCT01609881
View directory record Official record
Conditions
Inflammation
Interventions
Acuvail, Placebo
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 6, 2026, 1:41 PM EDT
Completed No phase listed Observational

Computer Detection of Diabetic Retinopathy Compared to Clinical Examination

NCT01625598
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Photography of the retina, Retinal photography
Procedure
Lead sponsor
Digital Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Mesa, Arizona • Phoenix, Arizona • Cedar Rapids, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Oct 6, 2026, 1:41 PM EDT
Completed No phase listed Observational

Pediatric Type 1 Diabetes and Retinopathy

NCT02691312
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Digital Retinography System
Device
Lead sponsor
University of Florida
Other
Eligibility
9 Years to 26 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
De Leon Springs, Florida • Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 6, 2026, 1:41 PM EDT
Recruiting Phase 2 Interventional

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

NCT07812090
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF, Sham
Drug · Other
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 6, 2026, 1:41 PM EDT
Completed Phase 1 Interventional Results available

Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery

NCT01069341
View directory record Official record
Conditions
Rubeosis Iridis, Proliferative Diabetic Retinopathy
Interventions
Ranibizumab
Drug
Lead sponsor
Bhagat, Neelakshi, M.D., M.P.H.
Individual
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 6, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

NCT04505566
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements
Drug · Other
Lead sponsor
Stephen J. Kim, MD
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 6, 2026, 1:41 PM EDT
Completed No phase listed Observational

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

NCT07105228
View directory record Official record
Conditions
Retinal Vasculitis
Interventions
aflibercept 2mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
290,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 6, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders

NCT00071227
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion
Interventions
Triamcinolone Acetonide (TAC-PF)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 6, 2026, 1:41 PM EDT
Completed No phase listed Observational

Long Term Follow-Up of Diabetic Retinopathy

NCT00001395
View directory record Official record
Conditions
Blindness, Cataract, Diabetes Mellitus, Diabetic Retinopathy, Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 6, 2026, 1:41 PM EDT
Completed Not applicable Interventional

Diabetic Retina Exam Rate Does Not Increase With Phone Reminders in Non-HMO Population

NCT00799695
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
phone call contact
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 1, 2008 · Synced Oct 6, 2026, 1:41 PM EDT
Completed Phase 3 Interventional

Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control

NCT01323348
View directory record Official record
Conditions
Diabetes, Diabetic Retinopathy
Interventions
Diabetes Education
Behavioral
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Loma Linda, California • Santa Barbara, California • Fort Lauderdale, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 6, 2026, 1:41 PM EDT
Completed Phase 2 Interventional

Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

NCT00536692
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
mecamylamine
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2008 · Synced Oct 6, 2026, 1:41 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Treating Early Stage Diabetic Retinopathy

NCT05132660
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Sinemet CR, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 6, 2026, 1:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Tracking Optical Coherence Tomography

NCT00343603
View directory record Official record
Conditions
Macular Degeneration, Glaucoma, Diabetic Retinopathy, Choroidal Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 6, 2026, 1:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Vascular Reparative Mechanism in Diabetes

NCT02119689
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Diabetic Patients, Healthy Controls
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 6, 2026, 1:41 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Adaptive Optics for Ophthalmic Technologies

NCT02826655
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
WF-AO-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 6, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema

NCT00069056
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Laser Treatment
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 6, 2026, 1:41 PM EDT
Completed No phase listed Observational

Resistance to Antibiotics in Patients Receiving Eye Injections

NCT02126423
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Conjunctival and nasopharyngeal swabs
Other
Lead sponsor
Prism Vision Group
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 6, 2026, 1:41 PM EDT
Completed Early Phase 1 Interventional

Photobiomodulation for the Treatment of Diabetic Macular Edema

NCT02457975
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
670nm PBM, intravitreous VEGF-inhibitors
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 6, 2026, 1:41 PM EDT
Completed Phase 4 Interventional

Ocular Safety and Usability Study for FYB203 PFS

NCT06708637
View directory record Official record
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
FYB203 2 mg (0.05 mL of 40 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Redlands, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 6, 2026, 1:41 PM EDT